Last reviewed · How we verify
NCT01125579
NEURAPAS Balance in Children With Nervous Restlessness, e.g. Agitated Depression
trial in Nervousness in 115 participants. Completed in 1 November 2008.
1 November 2008
Quick facts
| Lead sponsor | Pascoe Pharmazeutische Praeparate GmbH |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 115 |
| Start date | 1 March 2008 |
| Primary completion | 1 November 2008 |
| Estimated completion | 1 November 2008 |
| Sites | 1 location across Germany |
Conditions studied
- Nervousness — all drugs for Nervousness →
- Restlessness — all drugs for Restlessness →
- Depression (Agitated) — all drugs for Depression (Agitated) →
- Affective Disorders — all drugs for Affective Disorders →
Sponsor
Pascoe Pharmazeutische Praeparate GmbH — full company profile →
Who can join
Adults 6 to 11, any sex, with Nervousness or Restlessness. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Change in Parent Child Behaviour Checklist (CBCL/4-18)
Time frame: after 2 + 4 weeks´ treatment
Parent Child Behaviour Checklist (CBCL/4-18), standardized questionnaire
Sponsor's own description
Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12. Each patient is treated with NPB. No placebo group is established. Course and severity of symptoms is documented by a questionnaire on 13 common symptoms of nervous restlessness and a Visual Analogue Scale (VAS). A standardized questionnaire (Parent Child Behaviour Checklist (CBCL/4-18)) is completed. Choice and doses of therapy are at the respective physician's discretion. The planned treatment and observation period is 2 - 4 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01125579
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Pascoe Pharmazeutische Praeparate GmbH trials
Trials by the same sponsor.
- NCT05561257 — Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster · Phase 2 · terminated
- NCT06983847 — A Long-term Observational Study to Describe the Use of Vitamin-C Injektopas® 7.5 g in Patients With Vitamin C Deficiency · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01125579 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pascoe Pharmazeutische Praeparate GmbH
- Last refreshed: 14 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01125579.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing